Tumour Necrosis Factor Alpha-308 Gene Locus Promoter Polymorphism: An Analysis of Association with Health and Disease
Maqsood M. Elahi, Kamlesh Asotra, Bashir M. Matata, Sarabjit S. Mastana

To cite this version:
Accepted Manuscript

Tumour Necrosis Factor Alpha-308 Gene Locus Promoter Polymorphism: An Analysis of Association with Health and Disease

Maqsood M. Elahi, Kamlesh Asotra, Bashir M. Matata, Sarabjit S. Mastana

PII: S0925-4439(09)00022-2
DOI: doi:10.1016/j.bbadis.2009.01.007
Reference: BBADIS 62917

To appear in: BBA - Molecular Basis of Disease

Received date: 6 November 2008
Revised date: 16 January 2009
Accepted date: 20 January 2009

Please cite this article as: Maqsood M. Elahi, Kamlesh Asotra, Bashir M. Matata, Sarabjit S. Mastana, Tumour Necrosis Factor Alpha-308 Gene Locus Promoter Polymorphism: An Analysis of Association with Health and Disease, BBA - Molecular Basis of Disease (2009), doi:10.1016/j.bbadis.2009.01.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Tumour Necrosis Factor Alpha -308 Gene Locus Promoter Polymorphism: An Analysis of Association with Health and Disease

Maqsood M Elahi¹, Kamlesh Asotra², Bashir M Matata ³, Sarabjit S Mastana¹.

1. Department of Human Sciences, Human Genetics Laboratory, Loughborough University, Leicestershire, United Kingdom
2. Cardiovascular Disease and General Biomedical Sciences, University of California, Office of the President, Oakland, CA
3. Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom.

Short Title: TNF–308 (G>A) polymorphism and human disease.

Keywords: Systemic inflammatory response, Inflammatory markers, Genetics, Cardiovascular disease, Cancer, Rheumatoid Arthritis, Single nucleotide polymorphisms

Correspondence to:
Bashir M Matata, PhD
Liverpool Heart & Chest Hospital NHS Trust,
Thomas Drive, Liverpool, L14 3PE, United Kingdom
Email: matata_bashir@hotmail.com
SUMMARY

Tumour necrosis factor-alpha (TNF-α) is a potent immunomediator and proinflammatory cytokine that has been implicated in the pathogenesis of a large number of human diseases. The location of its gene within major histocompatibility complex and biological activities has raised the possibility that polymorphisms within this locus may contribute to the pathogenesis of wide range of autoimmune and infectious diseases. For example, a bi-allelic single nucleotide substitution of G (TNFA1 allele) with A (TNFA2 allele) polymorphism at -308 nucleotides upstream from the transcription initiation site in the TNF-α promoter is associated with elevated TNF-α levels and disease susceptibilities. However, it is still unclear whether TNF-α-308 polymorphism plays a part in the disease process, in particular whether it could affect transcription factors binding and in turn influence TNF-α transcription and synthesis. Several studies have suggested that TNFA2 allele is significantly linked with the high TNF-α -producing autoimmune MHC haplotype HLA-A1, B8, DR3, with elevated serum TNF-α levels and a more severe outcome in diseases. This review discusses the genetics of the TNF-α -308 polymorphism in selected major diseases and evaluates its common role in health and disease.
INTRODUCTION

Tumour necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that produces left ventricular dysfunction, cardiomyopathy, pulmonary oedema and a variety of other diseases, when over-expressed [1-2]. Recent observations showed that levels of circulating TNF-α are elevated in patients with unstable angina, rheumatoid arthritis (RA) and autoimmune disorders [3]. Although exact clinical significance of these findings is uncertain, given that TNF-α produces negative effects, it has been postulated that the elaboration of this proinflammatory cytokine may contribute to the progression of the disease process. Important to the above hypothesis regarding the pathophysiological role of TNF-α in disease is the elucidation of the mechanisms by which this proinflammatory cytokine exerts its effects. Although experimental studies from a number of laboratories have begun to explore the basic mechanisms of TNF-α at the tissue and cellular levels, until recently polymorphism in the promoter region of the TNF was found to be linked with the genetic basis for these diseases.

Circulating TNF-α levels and their genetic associations between gene polymorphisms are involved in many diseases and clinical endpoints, e.g. rejection after heart, kidney and liver transplantation and with a wide variety of other diseases [4-6]. The reasoning behind the proposed involvement of TNF gene polymorphisms in diseases either/or disease manifestations is that they may influence in-vivo cytokine levels. This presumption is based on the observation that individuals differ with respect to the level of cytokine production after in vitro culture of their cells and that these differences may be attributed partly to single nucleotide (SNP) or microsatellite polymorphisms within its corresponding gene [7]. These associations have not always been robust, replicable and consistent, for example some studies could not show a relationship between TNFA -308 gene polymorphism and liver graft rejection [8]. The generally held view is that genetic factors may affect TNF-α levels and the location of TNF locus is within the Class III region of the human major histocompatibility complex (MHC; also known
as TNFβ) on chromosome 6p21 conducive to its role in disease processes [9]. A number of SNP and other polymorphisms have been identified in the TNF locus, some of these have also been shown to influence the rate of transcription and protein production of TNF-α and TNFβ associations with diseases [10].

In the light of these conflicting results we reviewed the literature of available studies to clarify the role of -308 G/A polymorphism of the TNF gene and the disease risk. There is explosion of information on the disease associations with genetic polymorphism and it is impossible to keep up with published literature. We have listed the main research studies on TNF -308 and disease associations with reference to geographical regions in Table-1 [6, 9, 11-40]. In text, we discuss only the main points and linkages published in the literature.

**Biological Regulation of TNF-α Production and Function**

The biological functions of the TNF-α are varied and complex, where on one hand it confers disease resistance and on the other causes pathological complications. Indeed, TNF-α plays contradictory role which may be related to genetic polymorphisms in the genes regulating its production and effect. In the acute situation, local production of TNF-α is clearly beneficial. It increases the expression of adhesion molecules on the vascular endothelium to allow immune cells, in particular neutrophils and macrophages, to translocate to sites of tissue damage and infection [41]. Furthermore, TNF-α activates phagocytes to engulf and clear infectious agents and cellular debris. However, systemic or protracted exposure to TNF-α may be harmful. High levels of circulating TNF-α are associated with toxic shock induced by bacterial endotoxins [42] and derangements of metabolism in surgery or trauma patients may be related to the cachetic properties of this cytokine. The induction of interleukin-1 and interleukin–6 production stimulated by TNF-α leads to elevated temperature, sleepiness and the release
of glucocorticoids [43]. These may be short-term value in combating certain infections, but their long-
term effects are likely to be detrimental.

TNF-α itself can suppress the production of more TNF-α, an effect mediated through the TNFR1 and
TNFR2 cell surface receptors for TNF-α. Cells from mice deficient of TNFR1 or TNFR2 produce
substantially more TNF-α upon stimulation. Although TNF-α may be produced by many cell types,
macrophages are the main source of this cytokine. TNF-α is produced as a membrane-bound 26kD
molecule from which is released the soluble 17kD active TNF-α molecule by enzymatic cleavage. The
enzyme involved is a metalloproteinase disintegrin called TNF-α converting enzyme (TACE).
Remarkably, TACE also acts on membrane anchored TNFR2 protein thus controlling the amount of
soluble circulating TNFR2. This adds another layer to the regulation of TNF-α function because soluble
TNF receptor affects the activity of TNF-α [44].

Studies of TNF-α function in genetically manipulated mice have demonstrated that when homozygous
TNF-α gene knockout mice (no TNF-α production) were infected with the bacterium, Corynebacterium
Parvum, there was little or no initial response but the mice went on to develop a severe and fatal
inflammatory reaction [45]. By contrast, normal mice developed an inflammatory response that
resolved. This suggests that TNF-α has dual function, being proinflammatory in the initial infection and
then anti-inflammatory or immunoregulatory in the later phases of the response. Heterozygous mice,
those with only one active TNF-α gene were more susceptible to endotoxin-induced shock and certain
infections. In fact, in one strain of genetically manipulated mice deficient in TNF-α production, an
arthritic condition akin to ankylosing spondylitis developed [46]. Again, these observations are
consistent with a dual role for TNF-α, acting as a proinflammatory agent to start with, but later having
anti-inflammatory or immunoregulatory functions. Indeed, recent studies have shown that tumor
necrosis factor alpha can autoregulate by activating PIAS1 [protein inhibitor of activated STAT1
(signal transducer and activator of transcription 1) SUMO E3 ligase through a SUMO-dependent, inhibitor of kappaB kinase alpha (IKK alpha)-mediated phosphorylation event. Once activated PIAS1 is then recruited to the TNF-α gene promoter to repress transcription [47].

The TNF gene is located in close proximity to the HLA-B locus in both humans and mouse. The 5' flanking region of the TNF gene contains multiple potential regulatory sites, including consensus sequences for the AP-1 and AP-2 sites, the cAMP-responsive element, and sequences similar to the kappa B sequences found in immunoglobulin and cytokine regulatory elements [48]. This sequence has been demonstrated to be responsive to LPS and TNF stimulation. The 3' untranslated region contains a sequence element affecting posttranslational control of TNF through mRNA stability and translation efficiency. The functional importance and interactions of these regulatory elements remain undefined.

Experimental evidence suggests that phospholipase A2 and the lipoxygenase pathway may be central in the process of TNF induction in leukocytes. Down-regulation of TNF expression on the other hand is better understood. The inhibition of expression appears to result from high levels of cAMP, frequently induced through the action of PGE2. TNF secretion is separately regulated and may involve the action of G binding proteins [48]. In another study, posttranslational control of TNF-alpha release in LPS-stimulated alveolar macrophages exposed to the stress response was shown to be due to binding and sequestration by heat shock proteins (HSP) [49].

**TNF-α Gene Polymorphism and Cytokine Production**

The TNF-α gene is located on the short arm of chromosome 6 within the major histocompatibility complex, where genetic alterations in the TNF-α locus are now known to be involved directly in high TNF-α production [10]. Several polymorphisms have been identified inside the TNF-α promoter positioned at (relative to the transcription start site) −1031 (T→C), −863 (C→A), −857 (C→A), −851
(C→T), −419 (G→C), −376 (G→A), −308 (G→A), −238 (G→A), −162 (G→A), and −49 (G→A), although those at positions −419, −163, −49 are rare in Caucasians (Figure-1). Among these variants, a polymorphism that directly affects TNF-α expression is located at nucleotide position −308. A single-base polymorphism within the promoter of the gene for TNF-α results in 2 allelic forms, one in which guanine defines the common allele (TNFA*1) and the other in which guanine is substituted by adenosine forms the rarer allele (TNFA*2) at position −308. The presence of the rarer TNFA*2 allele has been found to correlate with enhanced spontaneous or stimulated TNF-α production in both in vitro and in vivo [50]. SNP in the TNF-α gene itself are more likely to be of direct functional significance in terms of regulating TNF-α production, as there are many SNP within the TNF-α gene promoter. In particular, there is interest in those polymorphic sites in the regulatory regions of the TNF-α gene that coincides with the DNA motifs to which transcription factors bind. In vitro stimulation of TNF-α production by cells from −308*G/G homozygous individuals and G/A heterozygote individuals have produced conflicting results. Two studies have reported higher TNF-α production by cells from G/A donors than by G/G cells [51]. Other studies have reported no significant affect [52-53]. However, it is interesting to note that these studies used different LPS concentrations and the number of individuals with the G/A genotype studied was in most of the cases small, affecting the power of the study to detect any significant difference between the genotypes.

Gene reporter assays have been employed to investigate the −308 SNP and again, contradictory results were reported. It was suggested that the A allele does influence TNF-α gene transcription [8] while others have concluded that it does not [54]. There are many variables affecting the results of this type of experiments; including the length of the promoter sequence used, the presence or absence of the 3′ UTR, the cell type used for transfection, and whether it is of human or non-human origin. Different
studies have used different approaches, thus making it difficult to draw a general conclusion. So far, evidence suggests that circulating TNF-α levels do not seem to correspond with the −308 TNF promoter polymorphisms. However, although circulating TNF-α level might be under a multifactoral regulatory process, local TNF-α concentration might be of greater importance and under more control by specific polymorphisms [55].

An analysis of the evaluation of the extended MHC haplotypes including the TNF region has been presented recently in which it was proposed that there are three ancient extended haplotypes from which the complex modern haplotypes were derived by mutation or crossover. In this analysis, the −308*G, -238*G haplotype was generally associated with low TNF-α production while either the −308*A allele or the −238*A allele were associated with high TNF-α production [56].

However, there are many biological steps, apart from the influence of the gene polymorphisms on TNF-α production, for which the control, production and release of TNF-α and its activity are regulated.

**Genetic Associations between TNF -308G/A Polymorphisms and Disease**

The polymorphism in the human TNF-α gene encoding high TNF-α levels may be important in the susceptibility or severity of diseases and in other inflammatory conditions as discussed below.

**TNF-α Genotypes in Parasitic, Bacterial and Viral Infections**

In parasitic infections, the −308*A allele has been associated with a fourfold increase in risk for cerebral malaria and a sevenfold increase in risk for development of serious neurological consequences [57]. This association was shown to be independent of the inheritance of HLA antigens. A similar study confirmed the association with the −308*A allele in the population of Sri Lanka [58] whereas in the West Africans the −376 alleles are in strong positive linkage disequilibrium with the −238 alleles and in
strong negative linkage disequilibrium with the –308 alleles [59]. Furthermore, the –376*A allele was found a risk factor independent of the –308*A allele for the development of cerebral malaria. Taken together, these results suggest that there are two genetic effects operating independently, however, its mechanism is yet unclear.

The –308*A allele was also associated with the most severe outcome, mucocutaneous leishmaniasis [60]. Hence both the risk of infection and its course may be associated with polymorphisms in TNF gene. In multiple injured patients with severe sepsis the TNFA*2 allele acts as a predictor of severe post traumatic sepsis and increased levels of circulating TNF-α [61-62]. It is interesting to note that the –308*A allele has been associated with severe septic shock and death. Several studies have investigated the association between TNF alleles and viral infections. The –238*A allele was associated with chronic infection with hepatitis B virus. No similar findings were found for –308 polymorphisms [63]. Similar findings were also reported for hepatitis C virus infection, the –238*A allele being associated with chronic hepatitis while the –308 alleles were not [64]. A comparison of Cytomegalovirus (CMV) positive and negative healthy adults showed that the frequency of the TNF-α –308*A allele was slightly increased in the seronegative individuals [65]. However, this reached statistical significance only when the genotype of another cytokine that influences the inflammatory response, interleukin-1 receptor antagonist was taken into account.

**TNF polymorphisms and Autoimmune Diseases**

In autoimmune diseases, TNF-α is one of the most studied genes. As most autoimmune diseases are associated with HLA, results of TNF polymorphism studies could be interpreted by linkage disequilibrium with HLA or, vice versa.
**Systemic Lupus Erythematosus:** In systemic lupus erythematosus (SLE), there is an association with -308*A allele and also a strong association with the HLA-DR3 antigen. The association between SLE and TNF genotype might best be explained by the strong linkage disequilibrium between the –308*A allele and the HLA-A1, B8, DR3 haplotypes. The TNF-308*A was shown to be associated with SLE in this ethnic group independent of any HLA-DR associations [66].

**Rheumatoid Arthritis:** In rheumatoid arthritis (RA) joints, there is an abundance of TNF-α so it was predicted that TNF-α gene polymorphism is associated with the disease. Further analysis found no association between the –308 alleles and RA. There is an association between HLA-DR4 and RA but there is a lack of linkage disequilibrium between the TNF–308 polymorphism and this HLA antigen. More recently, other TNF-SNP polymorphisms have been shown to correlate with the severity of RA but not with the initial susceptibility to the disease [3]. In order to better understand the genetic background of juvenile rheumatoid arthritis (JRA) several studies have been carried out recently. A study by Date et al [67], demonstrated that the -857T allele of the TNF alpha gene which was related to high production of tumor necrosis factor alpha, was associated with systemic JRA and that the -857T allele may enhance the effect of the DRB1*0405/DQB1*0401 haplotype in predisposing to the development of systemic JRA. Ozen et al [68], studied a group of 51 Turkish JIA patients and a second group consisted of 159 JIA patients from the Czech Republic. Healthy individuals (93 and 100) from each country served as controls. In both JIA cohorts, the distribution of genotypes was not significantly different among the types of JIA. The G-->A -238 polymorphism did not have an effect on the patients' outcome in either group. The G-->A -308 polymorphism was significantly associated with a poor outcome in the Turkish group (P=0.005) but not in the Czech patients. Another recent study examined the association of multiple TNF SNPs with juvenile oligoarthritis by constructing and analysing SNP-
tagged TNF haplotypes [69]. A total of 144 simplex families consisting of parent and affected child, as well as 88 healthy, unrelated control subjects were available for study. In these individuals, 9 polymorphic positions of TNF were typed by a high-throughput genotyping method based on the SNaPshot assay. The results demonstrated that TNF locus is linked and is associated with juvenile oligoarthritis and that information on the htSNPs can be useful in genetic studies of diseases in which TNF may be of relevance. In addition, a study Schmeling et al [70] on Caucasian subjects on TNF-alpha promoter polymorphisms at positions -163, -238, -244, -308, -376 to determine the association with disease in 228 patients with JIA and 196 healthy individuals. Genomic DNA was isolated and a PCR fragment of about 500 base pairs of the TNF gene promoter were amplified by PCR. Detection of polymorphisms was achieved by a single sequencing procedure. The results demonstrated that TNF promoter polymorphisms may play a role in the pathogenesis of JIA. The TNF-238A allele seems to be associated with juvenile psoriatic arthritis. The TNF-308A allele is less frequently found in rheumatoid factor negative but not in rheumatoid factor positive polyarthritis and may therefore be associated with a more severe disease, while the more common TNF-308G allele may be protective.

As the pathophysiology of RA becomes better understood, new therapeutic strategies and agents have been developed [71]. The efficacy of early and aggressive treatment with disease-modifying anti-rheumatic drugs (DMARDs) has now been studied. DMARDs, such as methotrexate (MTX), sulfasalazine (SSZ) and leflunomide, have documented prevention of the structural damage of the joints [72-73]. Recently, biologic response modifiers targeting specific cytokines, such as tumor necrosis factor-α (TNF-α) or interleukin-1, have been introduced, and the results indicated the effective suppression of the RA activity. However, the outcome of the treatment with DMARDs in RA patients is known to vary among patients. Recent advances in genetics have clarified that these individual differences are based on genetic polymorphisms, and this knowledge has encouraged the application of
pharmacogenetics to the treatment of RA. The difference in the response has been reported in biologic response modifiers and that in the case with the tumour necrosis factor (TNF) blocking agents, 20-40% of patients have been described as non-responders [74]. A recent study by Padyukov et al [74] analysed whether polymorphisms of several cytokine genes are associated with the responsiveness to TNF blockade with etanercept. 123 patients with active RA were treated with etanercept and response rates were determined after three months using American College of Rheumatology (ACR)20 and disease activity score (DAS)28 response criteria. Genotyping was done for TNF (-308 TNFA), interleukin (IL)10 (-1087 IL10), transforming growth factor (TGF)beta1 (codon 25 TGFB1), and IL1 receptor antagonist (intron 2 IL1RN). The results indicated that 24 patients (20%) were defined as non-responders owing to their failure to fulfil any of the ACR20 or DAS28 response criteria. None of the recorded alleles was alone significantly associated with responsiveness to treatment. However, a certain combination of alleles (-308 TNF1/TNF1 and -1087 G/G) was associated with good responsiveness to etanercept (p<0.05). In addition, a combination of alleles influencing interleukin 1 receptor antagonist (IL1Ra) and TGFbeta1 production (A2 allele for IL1RN and rare C allele in codon 25 of TGFB1 gene) was associated with non-responsiveness (p<0.05). The study concluded that genetic polymorphisms, which may influence the balance of pro- and anti-inflammatory cytokines of relevance for the course of RA, are associated with clinical responsiveness to etanercept treatment.

**Ankylosing Spondylitis**: On the other hand, tumor necrosis factor-alpha also has a prominent role in the inflammatory process and bone resorption in patients with ankylosing spondylitis (AS). Indeed, a recent study by Woo et al [75], evaluated the markers of clinical efficacy and bone biochemical changes in Korean patients with AS treated with etanercept therapy. The authors demonstrated that in patients with AS, etanercept therapy may be effective at reducing disease activity and improving bone
biochemical markers and that matrix metalloproteinase 3 (MMP-3) may be a useful biomarker for monitoring etanercept therapy. Indeed, changes in MMP-3 had a high correlation coefficient with changes of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) upon etanercept treatment (CRP, $r = 0.446$, $p = 0.022$; ESR, $r = 0.449$, $p = 0.021$). In another study [76] by Maksymowycz et al, where the authors determined whether a vertebral corner that demonstrates an active corner inflammatory lesion (CIL) on magnetic resonance imaging (MRI) in patients with AS is more likely to evolve into a de novo syndesmophyte visible on plain radiography than is a vertebral corner that demonstrates no active inflammation on MRI. MRI scans and plain radiographs were obtained from 29 patients recruited into randomized placebo-controlled trials of anti-tumor necrosis factor alpha (anti-TNF-alpha) therapy. New syndesmophytes developed significantly more frequently in vertebral corners with inflammation (20%) than in those without inflammation (5.1%) seen on baseline MRI ($P \leq 0.008$ for all reader pairs). They also developed more frequently in vertebral corners where inflammation had resolved than in those where inflammation persisted after anti-TNF treatment.

However, studies are divided as to whether TNF-alpha polymorphisms play a role on the pathogenesis of spondyloarthritis conditions. Earlier findings by Verjans et al [77] and Fraile et al [78] found no direct evidence to suggest TNF-alpha polymorphisms have an independent effect on AS susceptibility. In addition, Kaijzel et al [79] concluded in their study that an association between TNF-238G and AS is secondary to the HLA-B27 gene and that TNF-238 and TNF-376 alleles are not likely to be independently involved in the susceptibility to AS. In contrast, similar study by McGarry et al [80], showed -308 TNF-alpha gene allele-1 was significantly increased in patients with AS. Another study by Rudwaleit et al [81] showed that in HLA-B27 positive AS subjects, TNF-alpha gene 1/2 heterozygosity at -308 was associated with a higher percentage of TNF-alpha production and T cell numbers as
compared with TNF-alpha gene 1/1 homozygosity. Vargas-Alarcon and colleagues also demonstrated that TNF-alpha -308 promoter polymorphism was associated with the genetic susceptibility to undifferentiated ankylosing spondylitis [82] with a similar pattern was also observed in AS patients in a study by Shiau et al, in Taiwan [83]. A more recent study by Lu et al [84], demonstrated that HLA-A33-B58-Cw10 haplotypes associated with TNF-alpha promoter -308(G/A) polymorphism might play an important role in disease pathogenesis of AS in Chinese population partially related to increased TNF-alpha production.

The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. However, there is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and that this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA) [85]. There is however, little evidence to suggest that TNF-alpha genetic diversity plays a role in the effectiveness of currently available anti-TNF treatments. Much of this information is discussed in a greater detail in the recent manuscript by Braun et al [85]. In brief, the anti-TNF-alpha agents currently available, infliximab (Remicade); Centocor), etanercept (Enbrel); Amgen) and adalimumab (Humira; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since no therapies with disease-controlling anti-rheumatic drugs are available for severely affected patients, especially with spinal disease. Thus, TNF blockers might even be considered as first-line immunosuppressive agents in patients with active AS and PsA who are not sufficiently treated by non-steroidal anti-inflammatory drugs and sulfasalazine, if peripheral arthritis is present. For infliximab, a dosage of 5 mg/kg at intervals between 6 and 12 weeks was necessary to constantly suppress disease activity; this is also a major aim of long-term treatment. No dose-finding studies have yet been
performed. The standard dose of etanercept is 25 mg s.c. twice-weekly. No studies on adalimumab (standard RA dose 20 - 40 mg s.c. every 2 weeks) have yet been conducted in SpA. The efficacy of etanercept was first demonstrated in PsA and etanercept is now approved for this indication. A double-blind study has also been performed in AS, with similarly clear-cut efficacy [85]. There is preliminary evidence that both agents do also work in other SpA such as undifferentiated SpA.

Insulin dependent diabetes mellitus (IDDM) is strongly associated with the inheritance of the HLA DR3 and DR4 antigens. Studies of SNP have revealed weak association with the TNF –308*A allele, but in each study this could also be attributed to linkage disequilibrium with HLA-DR3 [86]. Similarly, the investigation of the TNF genotypes in Type II diabetes have demonstrated that 308 TNF-α gene polymorphism may contribute to CHD risk in patients with type-2 diabetes and it could constitute a useful predictive marker for CHD in type-2 diabetic women [25].

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system associated with HLA DR2 in North Europeans and North American Caucasians [87]. The TNFA−308 polymorphism was investigated by several groups, [88-89] none of these studies showed any significant association with MS.

**TNF Polymorphisms and Transplantation**

Biopsies from rejecting kidney or heart transplants show the presence of an inflammatory infiltrate of cells capable of producing TNF. Studies in kidney [14], heart transplant recipients [15] and liver [88] transplant recipients revealed an association between TNF A −308 polymorphisms and acute rejection. Death of heart transplant recipients as a consequence of irreversible acute rejection of their graft is exclusively confined to those of the TNFα−308*A genotype.
TNF-α Genotype in inflammatory conditions

Inflammation is a major component of a range of diseases. A TNFA –308*allele association is evident in the liver disease primary sclerosing cholangitis [89]. Equally, in primary biliary cirrhosis there was shown to be an association with the TNF –308* A allele shown in a group of Scottish patients awaiting liver transplants [90]. In addition, there are several inflammatory conditions of the gastrointestinal tract such as coeliac and crohn’s disease [13] that show a positive association with the –308*A allele, although the last is very weak. By contrast, in ulcerative colitis the –308*A allele seems to have a protective effect [91]

TNF-α Genotypes in Cancer

The influence of cytokine genotype on susceptibility to cancer or its prognosis has been considered. The areas looked at have been cancers of the immune system such as Non-Hodgkin’s lymphoma where the TNF-308*A and LT-α NcoI*1 alleles were found to be related to overall survival and progression free survival [92]. In chronic lymphocytic leukaemia again, the TNF–308 alleles were associated with the disease [93]. Hence high TNF production may promote the condition leading to the development of cancer, an indirect susceptibility factor for these diseases.

TNF-α Genotypes in Coronary Artery Disease

Coronary artery disease (CAD) is both multifactorial and polygenic in nature with atheroma formation, the pathological hallmark. CAD is an inflammatory process, with proinflammatory cytokines, such as TNF-α, having a major role in its pathogenesis [19]. Through its effects on lipid metabolism, insulin resistance and endothelial function, TNF-α is reported to be involved in the CHD. Whilst some reports
have suggested that –308 TNF-α gene polymorphism may contribute to CHD risk in patients, [4] others have found no evidence of influence on the CHD outcome [16].

**TNF-α Polymorphisms and Restenosis in Coronary Artery Disease**

Restenosis is still the main drawback of percutaneous transluminal coronary angioplasty (PTCA) [94]. It is thought to be multi-factorial process where recoil of the vessel, neointimal proliferation and thrombus formation are thought to play a role. Until now it has proved difficult to predict restenosis on clinical and procedural grounds, however, genetic epidemiology might provide more insights.

TNF-α has a broad spectrum of biologic activities and is predominantly known for its powerful proinflammatory effects [3]. In response to different stimuli such as mechanical injury of the arterial wall caused by stent deployment, a local inflammation is elicited that is characterised by adhesion and invasion of inflammatory cells. Tight control of gene activity and protein production may equilibrate the pro and the anti-inflammatory potentials of TNF-α and in turn prevent excessive inflammation and limit neointima formation [95]. However, imbalances in the regulation of this system may interfere with anti-inflammatory effects and stimulate proinflammatory activities that result in neointima formation and restenosis. The genes encoding TNF-α contain variable sites that may be associated with different responsiveness to regulatory signals. In particular SNP located in the promoter regions of the TNF-α gene (-308G/A) were found to differentially affect binding of nuclear transcription factors, transcriptional activity and/or protein production, [8, 52] characteristics that may be related to the unfavourable outcomes after coronary interventions.

**Effect of TNF-α Promoter on Transcriptional Activation**
Studies have suggested that the polymorphism at -308 has a significant effect on transcriptional activity in reporter gene assays and that this could explain the association between the high TNF-α phenotypes and the DR3 haplotype [8]. The molecular mechanism of this difference is not completely clear because no evidence was reported of a major difference in affinity of the DNA-binding protein(s) to the two allelic forms of the TNFA promoter. Perhaps as a result of difference in the DNA/chromatin structure at the polymorphic site, the interaction of transcription factors is enhanced leading to stronger transactivation of the TNF-α gene. Interestingly, a homologous sequence in the TNFA promoter (-254 to -230) has been shown to bind a transcriptional repressor and not AP2 [96]. It may be, therefore, that a novel protein binds to the polymorphic TNFA -308 site and evidence obtained from a study using both Jurkat and U937 cells has demonstrated binding of a novel protein only to the TNF2 allele [96]. A relatively recent study of TNF-α production from peripheral blood mononuclear cells stimulated with anti-CD3 and anti-CD28 has shown a higher TNF-α production phenotype in TNF2 carriers, and of two TNF haplotypes, differing only at -308, the TNF2 +ve haplotype produced significantly more TNF-α [74]. There is, therefore, evidence that the TNF2 genotype is associated with increased TNFα productions in vitro.

**TNF-α Gene Polymorphism Association in the Nutrition-Inflammation Axis**

The success of the Human Genome Project and the powerful tools of molecular biology have ushered in a new era of medicine and nutrition. This new era of molecular nutrition—that is, nutrient-gene interaction can unfold in dichotomous directions. One could focus on the effects of nutrients or food bio-actives on the regulation of the gene expression (i.e. nutrigenomics) or on the impact of variations in gene structure on one’s response to nutrients or food bio-actives (i.e. nutrigenetics). In a simple classification of nutritionally modifiable genes as being either constitutive or inducible, it is the second
order classification of these same genes as being either wild type or polymorphic that underlies the highly variable response of humans to a given diet (Figure-2). In order for TNF-α SNP to be a practical significance in the nutrigenetics paradigm, the SNP is likely to present with the number of characteristics such as exhibiting a high frequency in the general population of interest modifying or regulating proteins at the top of biological cascades or a rate limiting steps in intermediary metabolism and having attendant biomarkers that provide surrogate measures of clinical effect. At the present time there are only a few SNP that meet the criteria but from those that do we can learn a great deal.

CONCLUSIONS

Overall, TNF-α has been shown to be an important pro-inflammatory cytokine in disease and health. It is difficult to make general statements about the associations of TNF polymorphisms and TNFα production or pathology. The TNF polymorphisms are found in a region of great polymorphic variation and they are in linkage disequilibria with the HLA genes and with each other. Because of differences in the distribution of HLA alleles one might expect variation in associations between TNF polymorphisms and various conditions in different geographical areas. Indeed, there is a geographical variation in the frequency of the –308*A allele. It is present in approximately 5% of the population of South Africa compared with 30% in white Caucasians in the United Kingdom. Specimens from blood donors of regionally subdivided British population demonstrated significant differences exit among the subgroups of the population and it is argued that these may be involved in the invariable responses experienced in disease process [97].

Given the biological regulation of TNF-α and its role in the inflammatory process, it is perhaps surprising that the genetic influences on cytokine production have much influence on disease processes and their outcome. The associations between TNF-α genotype and disease are not absolute as suggested
by different conflicting studies (Table-1). Nevertheless, it is clear that the genetic regulation of TNF-α at sites of inflammation is important. Under circumstances where the release of TNF-α has been triggered the genetically endowed capacity for greater TNF-α production leads to more severe inflammatory reactions.

Given the relationship between TNF-α genotype and disease, the prognostic value of TNF-α genotyping is obvious, particularly in situations such as organ-transplantation where knowledge of the likely immune response to the graft may lead to modification of the immunosuppressive regimen. Other applications are readily foreseeable, too, so that genotyping for TNF-α polymorphisms is likely to be useful in many areas of medicine. To understand our personal uniqueness, nutrigenomics SNP is likely to open the door to the management and optimisation of our health through tailored nutrition. Clearly this is a lofty and distant goal; equally true is the fact that we have already started the journey towards it.

REFERENCES


59. J.C. Knight, I. Udalova, A.V. Hill, B.M. Greenwood, N. Peshu, K. Marsh, D. Kwiatkowski,
A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria, Nat Genet 22 (1999) 145-150.

60. M. Cabrera, M.A. Shaw, C. Sharples, H. Williams, M. Castes, J. Convit, J.M. Blackwell,


DECLARATION: We declare no conflict of interests

FIGURE LEGENDS

Figure 1: TNF complex on chromosome 6, showing location of microsatellites and SNPs (See reference 11)

Figure 2: Summary of the molecular nutrition hypothesis
Figure-1:

Class II

DP  DQ  DR

C4B  C4A  B1  C2

HSP  TNF

Class III

LT-β

TNF-α

LT-α

Class I

B  C  A

TNF f

TNFe, d

+696, +488

+70

-1031, EcoR1

-163, -238,

-851, -857, -863

AspHI, NcoI

TNF a,b
## Table 1: Characteristics of published studies showing the associations between TNF-α genotyping and disease outcome.

<table>
<thead>
<tr>
<th>Subcontinent/ Country</th>
<th>POPULATION/ REGION</th>
<th>DESIGN</th>
<th>DISEASE GROUP</th>
<th>NO of SUBJECTS</th>
<th>FINDINGS</th>
<th>ASSOCIATION</th>
<th>REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRICA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KENYA</td>
<td>Western Kenyan</td>
<td>Observational</td>
<td>Malaria</td>
<td>1,048 children</td>
<td>TNF2 homozygosity was associated with preterm birth, higher risk of death, high density of P. falciparum parasitemia, &amp; severe anaemia</td>
<td>TNF-308 promoter polymorphism allele 2 is a risk factor for early childhood mortality and malaria morbidity in children</td>
<td>Aidoo M et al., 200111</td>
</tr>
<tr>
<td>SOUTH AFRICA</td>
<td>Native Blacks</td>
<td>Case control</td>
<td>Systemic Lupus Erythematosus</td>
<td>98</td>
<td>Reduced TNF-2 allele level to disease</td>
<td>TNF-308 promoter polymorphism is not an independent risk factor to SLE</td>
<td>Rudwaleit M et al., 199612</td>
</tr>
<tr>
<td>EUROPE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BELGIUM</td>
<td>Belgian Caucasian</td>
<td>Non randomised receiving Infliximab Treatment</td>
<td>Fistulizing and Non Fistulizing Crohn Disease</td>
<td>226 patients + 128 Healthy</td>
<td>Frequencies for TNF-308 were not different for responders and non responders</td>
<td>TNF-308 promoter polymorphism is not associated with clinical response to treatment in Crohn’s Disease</td>
<td>Louis E et al., 200213</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>Natives</td>
<td>Retrospective Analysis</td>
<td>Kidney Transplants</td>
<td>157 patients</td>
<td>Tendency towards a increased risk of rejection episodes and worse survival in TNF-308/2 recipients (P&lt;0.02)</td>
<td>TNF-308/2 allele have significantly increased risk for early graft rejection</td>
<td>Wramner LG et al., 200414</td>
</tr>
<tr>
<td>Goteborg</td>
<td>Observational</td>
<td>Coronary artery bypass graft surgery</td>
<td>86 CABG patients</td>
<td>70 patients</td>
<td>Increased CAV and mortality in Homozygous for TNFA and TNFB</td>
<td>Positive association with homozygous TNFA and TNFB in morbidity and mortality.</td>
<td>Ternstrom L et al., 200515</td>
</tr>
<tr>
<td>Gothenburg</td>
<td>Observational</td>
<td>Meningococcal Disease</td>
<td>183 patients + 389 controls</td>
<td>190 patients</td>
<td>Frequencies for TNF-308 were not different in survivors and non survivors</td>
<td>TNF-α gene polymorphism does not influence the postop inflammatory process</td>
<td>Westerberg M et al., 200416</td>
</tr>
<tr>
<td>IRELAND</td>
<td>Dublin</td>
<td>Case control</td>
<td>Acute Pancreatitis</td>
<td>183 patients + 389 controls</td>
<td>Frequencies for TNF-308 were not different in survivors and non survivors</td>
<td>TNF-308 promoter polymorphism is not associated with disease outcome</td>
<td>Bulding J et al., 200317</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>Edinburgh/ Scotland</td>
<td>Case Control</td>
<td>Disease</td>
<td>190 patients</td>
<td>Frequencies for TNF-308 were not different in patients and controls</td>
<td>Genetic factors are not important in determining TNF-α secretion in</td>
<td>Powell JJ et al., 200118</td>
</tr>
<tr>
<td>Location</td>
<td>Type</td>
<td>Control</td>
<td>Disease</td>
<td>Patients</td>
<td>Comparison</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>------</td>
<td>---------</td>
<td>---------</td>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Blackpool</td>
<td>Case control</td>
<td>Coronary artery disease</td>
<td>One vessel (58), multi-vessel (122), normal et coronaries (79), Healthy (250)</td>
<td>No significant difference in TNF-α 308 was found between the groups</td>
<td>No correlation found b.w TNF-A 308 with the development of CAD.</td>
<td>Allen RA et al., 2001</td>
<td></td>
</tr>
<tr>
<td>FRANCE, Pessac</td>
<td>Observational</td>
<td>Coronary artery disease</td>
<td>Male CAD (299)</td>
<td>Genotype + 308 G/A TNF-α, A allele increase in unstable / stable angina (P= 0.029) and not in MI</td>
<td>Confirmation of crucial role of TNF-α in unstable angina</td>
<td>Bernard Vet al., 2003</td>
<td></td>
</tr>
<tr>
<td>GERMANY, Southern Germany</td>
<td>Case Control</td>
<td>Ankylosing Spondylitis</td>
<td>96 patients + 58 healthy</td>
<td>Reduced TNF -308/2 allele Expression in patients</td>
<td>TNF-308/2 is protective for AS in Southern German Population</td>
<td>Milicic A et al., 2000</td>
<td></td>
</tr>
<tr>
<td>Marburg</td>
<td>Case control</td>
<td>Chronic obstructive pulmonary disease</td>
<td>113 COPD, 113 CAD, 243 Healthy</td>
<td>No significant difference in TNF-α 308, TNF-B, IL-6 and IL-10 b.w COPD and counterparts</td>
<td>No correlation found b.w TNF-A 308 with altered/ abnormal inflammatory response</td>
<td>Seifart C et al., 2005</td>
<td></td>
</tr>
<tr>
<td>Bonn</td>
<td>Non randomised receiving immunosuppressive therapy</td>
<td>Aplastic Anaemia</td>
<td>56 patients + 117 healthy</td>
<td>Positive response to therapy among carriers of the TNF2 gene</td>
<td>TNF-308/2 is contributes to the pathogenesis and therapeutic response of AA</td>
<td>Demeter J et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Bonn</td>
<td>Clinical Coronary artery bypass surgery</td>
<td>CABG on CPB 47; CABG off pump 36</td>
<td>Homozygous TNF-B2 allele had increase TNF-α levels</td>
<td>Strong association reported</td>
<td>Schroeder S et al., 2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPAIN, Zaragoza</td>
<td>Case control</td>
<td>Peptic and Duodenal ulcer</td>
<td>130 DU + 50 PU patients + 102 healthy</td>
<td>Reduced TNF-308/2 frequency in PU in contrast to DU</td>
<td>TNF-308 allelic distribution contributes to the pathogenesis of PU and DU</td>
<td>Lanas A et al., 2001</td>
<td></td>
</tr>
<tr>
<td>Tarragona</td>
<td>Case control</td>
<td>Type Diabetes</td>
<td>235 CAD patients DM –ve; 106 CAD DM +ve; 135 DM CAD –ve, 207 health</td>
<td>Gender difference +ve. TNF-A/308 increased in CAD and with or without DM than controls (P= 0.0056)</td>
<td>308 TNF-α gene polymorphism contribute to CAD risk with DM</td>
<td>Vendrell J et al., 2003</td>
<td></td>
</tr>
<tr>
<td>Madrid</td>
<td>Case control</td>
<td>Celiac Disease</td>
<td>157 patients + 305 Healthy</td>
<td>TNF-2 (A) was increased in patients than controls</td>
<td>TNF-308 allelic distribution contributes to the pathogenesis of Celiac Disease</td>
<td>Fernandez L et al., 2002</td>
<td></td>
</tr>
<tr>
<td>ASIA</td>
<td>Locale</td>
<td>Study Type</td>
<td>Condition</td>
<td>Sample Size</td>
<td>Findings</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>----------------------</td>
<td>------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td>INDIA</td>
<td>Tamil Nadu/ Brahmint</td>
<td>Population based study</td>
<td>Schizophrenia</td>
<td>86 unrelated trios</td>
<td>Frequencies for TNF-308 A allelic were not associated with schizophrenic cases</td>
<td>Handoko HY et al., 2003</td>
<td></td>
</tr>
<tr>
<td>CHINA</td>
<td>Chinese Han</td>
<td>Case control</td>
<td>Schizophrenia</td>
<td>314 patients + 340 Healthy</td>
<td>Frequencies for TNF-308 G/A allelic were not different in patients and controls</td>
<td>Duan S et al., 2004</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Taiwanese</td>
<td>Case control</td>
<td>Type 2 Diabetic Mellitus</td>
<td>261 patients + 189 Healthy</td>
<td>G-308 promoter polymorphism and high fasting plasma glucose levels adjusted for age, sex, BMI and diabetic status was found</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INDONESIA</td>
<td>Sulawesi; ethnic groups</td>
<td>Population based study</td>
<td>Parasitic infection</td>
<td>150 Bugis, 168 Makassans and 58 Torajans</td>
<td>Significant differences exhibited at the TNF loci TNF-308/2 (p&lt;0.05)</td>
<td>Shiau MY et al., 2003</td>
<td></td>
</tr>
<tr>
<td>JAPAN</td>
<td>Tokyo &amp; Nagoya</td>
<td>Case control</td>
<td>Schizophrenia</td>
<td>297 patients + 458 Healthy</td>
<td>TNF-308G&gt;A polymorphism frequency of both the patients and control are low (1.5% and 0.8% respectively)</td>
<td>Hashimoto R et al., 2004</td>
<td></td>
</tr>
<tr>
<td>KOREA</td>
<td>Seoul</td>
<td>Population based study</td>
<td>-</td>
<td>80 individual from 20 normal Korean families + 133 unrelated healthy controls</td>
<td>TNF-308 A were found more frequently in Koreans (91.3%) than Caucasians (p&lt;0.001)</td>
<td>Kim HK et al., 2000</td>
<td></td>
</tr>
<tr>
<td>MIDDLE EAST</td>
<td>Palestinian &amp; Jordanian</td>
<td>Case control</td>
<td>Behcet’s Disease</td>
<td>102 patients + 115 Healthy</td>
<td>TNF-308/2 allele polymorphisms was not raised in blind and non blind subjects</td>
<td>Verity DH et al., 1999</td>
<td></td>
</tr>
<tr>
<td>OCEANIA</td>
<td>Australian Caucasian</td>
<td>Case control</td>
<td>Schizophrenia</td>
<td>65 patients + 151 healthy</td>
<td>Frequencies for TNF-308 A allelic were not associated with schizophrenic cases</td>
<td>Handoko HY et al., 2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Busselton</td>
<td>Population Based study</td>
<td>Asthma</td>
<td>1004 subjects from 230 families</td>
<td>TNF-308/2 was more strongly associated with disease (p=0.002); showed association with bronchial</td>
<td>Moffatt MF et al., 1999</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Region</td>
<td>Study Type</td>
<td>Disease</td>
<td>Participants</td>
<td>Frequencies for TNF-308 A allelic were not associated with schizophrenic cases</td>
<td>TNF-308 promoter polymorphism is not an independent risk factor to disease</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------</td>
<td>-----------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Fiji</td>
<td>Indigenous Fijian</td>
<td>Case control</td>
<td>Schizophrenia</td>
<td>134 patients + 92 Healthy</td>
<td>Frequencies for TNF-308 A allelic were not associated with schizophrenic cases</td>
<td>TNF-308 promoter polymorphism is not an independent risk factor to disease</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>North America</td>
<td>Clinical Trial</td>
<td>Rheumatoid Arthritis</td>
<td>457 subjects with early RA</td>
<td>No association</td>
<td>No association</td>
<td></td>
</tr>
<tr>
<td>Boston</td>
<td>USA</td>
<td>Prospective Observational Study</td>
<td>Asthma</td>
<td>708 children</td>
<td>No association</td>
<td>No association</td>
<td></td>
</tr>
<tr>
<td>Dallas</td>
<td>USA</td>
<td>Observational</td>
<td>Sepsis</td>
<td>159 patients with burns</td>
<td>TNF-α–308 A allele imparted 1.8 fold increase of developing sepsis</td>
<td>Strong association of TNF-α–308 polymorphism with sepsis</td>
<td></td>
</tr>
<tr>
<td>California</td>
<td>USA</td>
<td>Prospective Observational Study</td>
<td>Sickle-cell anaemia</td>
<td>230 children with SCA</td>
<td>The combination of TNF–308 GG homozygosity was associated with a particularly strong predisposition to large vessel stroke in SCA</td>
<td>TNF–308 play a role in predisposition to specific stroke subtypes in children with SCA</td>
<td></td>
</tr>
<tr>
<td>San Diego</td>
<td>USA</td>
<td>Case control</td>
<td>Asthma</td>
<td>Asthmatic (236) and non asthmatic(275)</td>
<td>TNF-α–308 A allele was correlated with asthma(P&lt;0.04)</td>
<td>↑ risk of asthma with TNF-α 308 * A</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Mastizos</td>
<td>Case control</td>
<td>Rheumatic heart disease with Mitral valve lesion and disease</td>
<td>87 patients + 101 healthy</td>
<td>MVD showed increased frequency of –308 (AG) and (A), while MVL showed increased frequency of –308 (A)</td>
<td>Distribution of –308 polymorphism was similar in MVD and MVL</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Mastizos</td>
<td>Case control</td>
<td>Systemic Lupus erythematosus</td>
<td>51 patients + 55 healthy</td>
<td>TNF-308 and genotype distribution failed to show any difference between disease process and healthy</td>
<td>TNF-308 does not play a any role in SLE</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMERICA</td>
<td></td>
<td>Prospective Observational Study</td>
<td>-</td>
<td>295 men + 389 women</td>
<td>Increased hs-CRP serum levels in individuals harbouring TNFA2 allele (p&lt;0.05)</td>
<td>Positive association of disease with the presence of TNFA2 allele</td>
<td>Araujo F et al., 2004</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>-------------------------------</td>
<td>---</td>
<td>-------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>BRAZIL</td>
<td>Native</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Figure-2:

Molecular Nutrition

“Nutrient-Gene Interaction”